Todd Peterson

Dr. Todd Peterson is the Founder and Principal of GenApex Bio, a life sciences advisory, investment, and board practice company based in Coronado, California. With over 35 years across academic research and industrial R&D, spanning molecular genetics, genomics, cell biology and synthetic biology engineering, his experience encompasses biotechnology, clinical diagnostics, life science research tools, drug discovery and industrial biotechnology markets, products, and technologies. Prior to GenApex Bio, Dr. Peterson was Chief Scientific Officer at the Allen Institute comprising foundational and applied research programs across its Brain Science, Cell Science, Immunology Institutes, and the Paul G. Allen Frontiers Group. Prior to the Allen Institute, Dr. Peterson was Chief Technology Officer at Synthetic Genomics (SGI) where he led an integrated team of scientists, engineers and informaticians to engineer diverse complex living systems. Before joining SGI, he led Synthetic Biology, Cloning and Protein Expression and Genomics R&D at Invitrogen/Life Technologies (now ThermoFisher), a global leader in life science research tools. Dr. Peterson has held industrial R&D leadership and bench scientist positions with increasing responsibilities at Genicon Sciences, Trega Biosciences, Hybritech, Gen-Probe and Immulok, focusing on technology development and product commercialization.

Dr. Peterson was a postdoctoral fellow at the Max Planck Institute in Cologne, Germany, received his Ph.D. in Microbiology at the University of Southern California School of Medicine, and received his M.A. in Biological Sciences and his B.A. in Molecular Biology and Biochemistry from the University of California, Santa Barbara.

Among his other engagements with life science companies, investors and research institutions, Dr. Peterson serves as Director on the Boards of the Center of Excellence for Engineering Biology (CEEB/GP-Write), Armata Pharmaceuticals (ARMP), Molecular Assemblies and NanoCellect BioMedical, and the Scientific Advisory Boards for Iridia, Karma Biotechnologies, Resolute Bio and Nanostring (NSTG).